Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

National Survey of Psoriasis Flares after 2009 Monovalent H1N1/Seasonal Vaccines

Sbidian E.a-c · Eftekahri P.d · Viguier M.e, f · Laroche L.k · Chosidow O.a-c · Gosselin P.l · Trouche F.m · Bonnet N.n · Arfi C.o · Tubach F.g-i · Bachelez H.e,f,j · for the Groupe de Recherche sur le Psoriasis from the French Society for Dermatology and the Syndicat National des Dermatologues-Vénéréologues

Author affiliations

aService de Dermatologie, Hôpital Henri-Mondor, AP-HP, bUFR de Médecine, Université Paris-Est Créteil, and cINSERM, Centre d'Investigation Clinique 006, Hôpital Henri-Mondor, AP-HP, Créteil; dCentre de Pharmacovigilance, Hôpital Fernand-Widal, AP-HP, eService de Dermatologie, Hôpital Saint-Louis, AP-HP, fSorbonne Paris Cité, Université Paris Diderot, gDépartement d'Epidémiologie et Recherche Clinique, Hôpital Bichat, AP-HP, hUFR de Médecine, Université Paris Diderot, Sorbonne Paris Cité, iCIE 801, INSERM, and jInstitut Imagine, Hôpital Necker-Enfants Malades, AP-HP, Paris; kDepartment of Dermatology, Hôpital Avicenne, AP-HP, Bobigny; lDermatologist, Bayonne; mDermatologist, Rodez; nService de Dermatologie, Hôpital Nord, Marseille; oDermatologist, Issy-les-Moulineaux, France

Related Articles for ""

Dermatology 2014;229:130-135

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 22, 2013
Accepted: April 03, 2014
Published online: August 23, 2014
Issue release date: October 2014

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM

Abstract

Background: Psoriasis is a common chronic immune-mediated disease resulting from interactions of a genetic background with environmental triggering factors such as stress and infection. So far, there is very limited information available about the impact of vaccine stimuli on psoriasis course. Objective: To collect cases of psoriasis flares occurring after vaccination through a national survey. Methods: We investigated cases of onset or flare of psoriasis occurring within 3 months following the 2009 monovalent H1N1/seasonal vaccination during the campaign of the 2009-2010 flu seasons in France. Results: Ten patients, 6 men and 4 women with a median age of 44 years (range 9-88), were reported with a psoriasis of new onset (n = 7) or with a worsening of previously diagnosed psoriasis (n = 3) within a median time period of 8 days following vaccination. Nine of them presented with a mixed guttate/plaque clinical phenotype, and 1 showed 2 successive generalized pustular psoriasis (GPP) flares after 2 different vaccine injections. Conclusion: The short time interval between vaccination and onset of psoriasis flares, the lack of other triggers and the flaring sequence following 2 different vaccines in a GPP patient suggest a possible association between the 2009 monovalent H1N1/seasonal vaccination and psoriasis flaring in the collected cases. Nevertheless, the likely very low incidence of psoriasis following vaccination emphasizes the safe profile and the relevance of vaccination strategies in psoriasis patients, especially in candidates for immunosuppressive treatments.

© 2014 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 22, 2013
Accepted: April 03, 2014
Published online: August 23, 2014
Issue release date: October 2014

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.